MSI1 already represents a potential therapeutic target for the treatment of glioblastoma, as luteolin has been shown to inhibit the RNA-binding properties of MSI1 and disrupts cancer phenotypes in glioblastomas [77]. The gene discussed is MSI1; the disease is cancer.